Friendly staff, clean facility. The doctor Tailor is very knowledgeable, friendly, and helpful.
— Asad Malik
Anti-VEGF Eye Injections: What to Expect
Anti-VEGF Medications Used in Treatment
Several anti-VEGF medications are available, each with its own dosing schedule and specific approvals. Your Retina Specialist will recommend the medication that best fits your condition, your eye's response, and your overall treatment goals.
Lucentis (ranibizumab) was the first anti-VEGF drug approved specifically for use in the eye. It is approved for wet AMD, DME, diabetic retinopathy, and retinal vein occlusions, and is typically given every four weeks, though some patients may be placed on an extended schedule. Several biosimilar versions of ranibizumab, including Byooviz and Cimerli, are now available and may be used in appropriate cases.
Eylea (aflibercept) is one of the most widely used anti-VEGF agents and is approved for wet AMD, DME, diabetic retinopathy, and retinal vein occlusions. It is typically given every four to eight weeks after initial monthly loading doses. Eylea HD is a newer, higher-dose formulation approved for wet AMD and DME that may allow longer intervals between injections after the loading phase, which can reduce the number of office visits required each year.
Avastin (bevacizumab) is FDA-approved for the treatment of certain cancers but is widely used off-label for retinal conditions. While it is not FDA-approved for use in the eye, large clinical studies have demonstrated its effectiveness for wet AMD and other retinal diseases. Many Retina Specialists use Avastin because of its well-established track record in clinical research. It is typically given every four to six weeks.
Vabysmo (faricimab) is a newer bispecific antibody that works differently from other anti-VEGF drugs. It blocks two proteins involved in retinal disease: VEGF and angiopoietin-2 (Ang-2). This dual action may provide more complete disease control. Vabysmo is approved for wet AMD and DME, and some patients may go up to sixteen weeks between injections, significantly reducing the treatment burden over time.
Beovu (brolucizumab) is approved for wet AMD and can be given every eight to twelve weeks after loading doses. However, it carries a known risk of retinal vasculitis (inflammation of blood vessels in the retina) and retinal artery occlusion (blockage of blood flow). Because of these risks, it is typically reserved for patients who have not responded well to other options, and patients receiving Beovu require close monitoring for signs of inflammation.
Who May Need Anti-VEGF Treatment
Certain health conditions and personal history factors can raise the likelihood of developing a retinal disease that requires anti-VEGF therapy. Knowing your risk can help you and your care team stay ahead of any changes in your vision.
Advanced age is the primary risk factor for wet AMD, the most common condition treated with anti-VEGF injections. Risk increases significantly after age 60. A family history of AMD also raises the likelihood of developing the condition, so people with a close relative affected by AMD should discuss regular screening with their eye care provider.
Diabetes is the leading cause of diabetic retinopathy and diabetic macular edema. The longer a person has had diabetes and the less controlled their blood sugar, the greater their risk of retinal damage. High blood pressure and cardiovascular disease also contribute to retinal vascular problems, including retinal vein occlusions. Managing these systemic conditions can help protect the retina over time.
Smoking is one of the most significant changeable risk factors for AMD and can substantially increase the risk of developing the disease. Quitting smoking at any age can help reduce this risk. A diet rich in leafy greens, fish, and antioxidants may also support retinal health, though lifestyle changes do not replace the need for treatment once a condition has developed.
Recognizing the Warning Signs
Retinal diseases can cause symptoms that range from subtle and gradual to sudden and severe. Knowing what to watch for helps you seek care at the right time, which can make a meaningful difference in your outcome.
Many retinal conditions develop slowly, and early signs can be easy to overlook. You may notice blurred central vision, difficulty reading fine print, a need for brighter light, or straight lines that appear wavy or distorted. This distortion is called metamorphopsia and is a common early symptom of conditions like wet AMD. Because these changes may only affect one eye at first, they can go unnoticed for some time.
Some retinal problems cause sudden symptoms that require urgent evaluation. A rapid increase in floaters, flashes of light, a shadow spreading across your vision, or sudden vision loss in one eye are warning signs of a serious problem. If you experience any of these symptoms, contact a Retina Specialist or go to the emergency room right away. Delaying care in these situations can lead to severe and irreversible vision loss.
How We Diagnose and Monitor Retinal Conditions
Before beginning anti-VEGF treatment, your Retina Specialist will perform a thorough evaluation using advanced imaging technology. These same tests are used throughout treatment to track how your eye is responding and guide any adjustments to your plan.
Your Retina Specialist will begin with a comprehensive dilated eye exam. Eye drops are used to widen the pupil, allowing for a detailed view of the retina. This exam can reveal abnormal blood vessels, fluid buildup, bleeding, and other signs of retinal disease. Visual acuity testing is also performed to measure how clearly you see at various distances.
Optical coherence tomography, or OCT, is a noninvasive imaging test that produces detailed cross-sectional images of the retina. It can detect fluid under or within the retinal layers, measure retinal thickness, and reveal structural changes at a microscopic level. OCT is one of the most important tools we use to diagnose retinal conditions and monitor how well treatment is working at every visit.
Fluorescein angiography uses a special dye injected into a vein in the arm to photograph blood flow through the retina. The dye reaches the eye within seconds, and a camera captures rapid images to identify leaking vessels, poor blood flow, and abnormal vessel growth. Indocyanine green (ICG) angiography works similarly and provides additional detail about deeper layers of the retina and underlying vasculature. Both tests help your Retina Specialist plan the most appropriate course of treatment.
The Injection Procedure
Most patients feel significantly less discomfort than they expect. Understanding each step of the process ahead of time can help reduce anxiety and help you feel more at ease during your appointment.
Before the injection, the eye is cleaned with an antiseptic solution to minimize the risk of infection. Numbing drops or a small application of local anesthetic are then applied to reduce discomfort. A small device called a lid speculum may be used to gently hold the eyelids open during the procedure. The preparation process typically takes just a few minutes.
The injection is performed using a very fine needle inserted through the white part of the eye, called the sclera, and into the vitreous cavity, the gel-filled space inside the eye. The medication is delivered in a very small volume, and the actual injection takes only a few seconds. Most patients describe the sensation as a brief pressure rather than sharp pain. The entire office visit, including preparation and a brief check afterward, typically takes about 30 minutes.
Immediately after the injection, you may notice floaters, mild redness on the white of the eye, or a gritty sensation. These effects are normal and usually resolve within a few days. Your Retina Specialist may check your eye pressure before you leave. Most people can return to their normal activities the same day, following any specific instructions provided by their care team.
Treatment frequency depends on the medication used and how your eye responds. Many patients begin with monthly loading doses, typically three to four injections given four weeks apart. After this phase, your Retina Specialist may extend the interval between visits using a treat-and-extend approach. With newer agents like Vabysmo and Eylea HD, some patients can go three to four months between injections. Individual needs vary, and your schedule will be adjusted based on your response.
What to Expect from Treatment
Anti-VEGF therapy offers meaningful benefits for most patients, but outcomes vary depending on the condition being treated, its severity, and how consistently treatment is maintained. Understanding what this therapy can and cannot do helps set realistic goals.
The primary goal of anti-VEGF treatment is to preserve your current vision and, when possible, improve it. Many patients with wet AMD experience stabilization of their vision, and a meaningful portion see improvement with consistent treatment. Results for DME and retinal vein occlusions are similarly encouraging. Not every patient will experience improvement, but the majority can expect their condition to stabilize with regular, ongoing care.
Anti-VEGF therapy requires a long-term commitment. Skipping or delaying injections can allow the disease to become active again, leading to new fluid leakage and further vision loss, some of which may not be recoverable. Keeping all scheduled appointments is one of the most important steps you can take to protect your sight. If barriers make it difficult to attend appointments, it is important to discuss those concerns with your Retina Specialist as early as possible.
Anti-VEGF injections have a well-established safety profile, and the most common side effects are mild and temporary, including slight redness, floaters, and a gritty or sore feeling. Serious complications are rare. Endophthalmitis, a severe infection inside the eye, is one of the most concerning potential risks, though it is uncommon when proper technique and sterile conditions are used. Seek immediate care if you develop severe eye pain, significant vision loss, increasing redness, or discharge from the eye within days of an injection, as these symptoms may indicate a medical emergency.
Living with Ongoing Anti-VEGF Treatment
For many patients, anti-VEGF therapy becomes a regular part of managing a chronic condition. There are practical tools and support resources that can make this long-term commitment more manageable.
Because ongoing treatment is essential, finding ways to stay organized makes a real difference. Using a calendar, setting phone reminders, or enlisting a family member to help track appointments can all make it easier to stay consistent. Some patients find it helpful to schedule injection visits on the same day each month or to coordinate them with other routine activities.
Between appointments, you can monitor your vision using an Amsler grid, which is a simple chart with a grid of straight lines and a central dot. By looking at the grid with each eye separately, you can detect new distortion, blurriness, or missing areas that may indicate the disease is becoming more active. Any new changes should be reported to your Retina Specialist promptly rather than waiting for your next scheduled visit.
Living with a chronic eye condition and undergoing regular injections can be stressful, and it is completely normal to feel anxious before appointments or worried about your vision. Talking with family, friends, or a counselor can help. Low-vision rehabilitation services and patient support groups are available for those who have experienced significant vision changes and are looking for additional guidance and community.
Frequently Asked Questions
Below are answers to questions our patients most often ask about anti-VEGF injections, focusing on practical details and decision guidance that can help you navigate your care.
Most patients are surprised by how little discomfort is involved. Numbing drops or local anesthetic are applied before the procedure, and the injection itself takes only a few seconds. The most common description is a brief sensation of pressure rather than sharp pain. Some mild soreness or irritation in the eye may occur in the hours that follow, but this typically resolves on its own within a day or two and does not usually interfere with normal activities.
For most conditions treated with anti-VEGF therapy, treatment is ongoing because the underlying diseases, including wet AMD and diabetic eye disease, are chronic and can reactivate if injections stop. As your condition stabilizes, your Retina Specialist may be able to extend the time between visits. The goal over time is to find the longest safe interval for your eye while keeping the disease under control, but this varies considerably from person to person.
All FDA-approved anti-VEGF drugs are effective at treating retinal conditions, but they differ in molecular structure, how long they remain active in the eye, dosing intervals, and approved uses. Vabysmo, for example, targets two proteins rather than one, and Eylea HD may allow longer periods between injections for eligible patients. Avastin is used off-label but has a strong evidence base from major clinical trials. Your Retina Specialist will recommend the medication that best fits your specific diagnosis, treatment history, and practical needs.
Any new or worsening visual symptoms between scheduled visits should be reported to your Retina Specialist right away rather than waiting for the next appointment. Symptoms such as increased floaters, new flashes of light, a sudden shadow across your vision, or any rapid decrease in vision may indicate that the disease has become more active or that a complication has developed. Severe eye pain, significant redness, or discharge following an injection are emergency symptoms that require same-day evaluation.
For most patients with wet AMD, DME, or retinal vein occlusions, anti-VEGF injections are the most effective treatment currently available. In selected cases, laser photocoagulation or steroid-based treatments such as a dexamethasone implant may be considered as alternatives or as supplements to injection therapy. Research into sustained-release delivery systems and gene therapy is ongoing. Your Retina Specialist can explain which options, if any, may be appropriate for your individual situation and goals.
OCT imaging is the primary tool used at every visit to measure retinal fluid and thickness, giving your Retina Specialist an objective view of whether the disease is active or controlled. Fluorescein and ICG angiography are used when a more detailed picture of blood vessel activity is needed, such as when planning treatment or evaluating a change in your condition. Together, these tests allow for precise, individualized adjustments to your treatment schedule rather than a one-size-fits-all approach.
Schedule a Retina Consultation at The Eye Center
Our visiting Retina Specialists bring fellowship-trained expertise in retinal disease, vitreoretinal surgery, and medical retina care to patients throughout Northern Virginia, with retina clinic services available at our Lansdowne office. Whether you are newly diagnosed or seeking a second opinion, we are here to provide thorough evaluation, advanced imaging, and personalized treatment planning every step of the way. Contact us today to schedule your consultation and take an important step toward protecting your vision.